{
    "Trade/Device Name(s)": [
        "VIDAS\u00ae CA 15-3 Assay"
    ],
    "Submitter Information": "bioM\u00e9rieux, Inc.",
    "510(k) Number": "K080469",
    "Predicate Device Reference 510(k) Number(s)": [
        "K010796"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LTK"
    ],
    "Summary Letter Date": "June 22, 2009",
    "Summary Letter Received Date": "February 27, 2009",
    "Submission Date": "February 26, 2009",
    "Regulation Number(s)": [
        "21 CFR 866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor-associated antigen immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "CA 15-3"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "VIDAS instruments"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme Linked Fluorescent Assay (ELFA)",
        "Two-step immunoassay sandwich method",
        "Fluorescent detection"
    ],
    "Methodologies": [
        "Immunoassay",
        "Enzyme-linked fluorescent assay"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for VIDAS CA 15-3 automated immunoassay for quantitative measurement of CA 15-3 in human serum to monitor breast cancer progression or recurrence.",
    "Indications for Use Summary": "Automated quantitative immunoassay for CA 15-3 in human serum, aiding in monitoring patients previously diagnosed with breast cancer for disease progression, response to therapy, and detection of recurrence in previously treated Stage II and III breast cancer patients.",
    "fda_folder": "Immunology"
}